AnaptysBio

Yahoo Finance • 10 months ago

13 Best Short Squeeze Stocks To Buy Now

In this piece, we will take a look at the 13 best short squeeze stocks to buy now. If you want to skip our primer on short squeezing, and some of the greatest short squeezes in history, then you can take a look at the 5 Best Short Squeeze... Full story

Yahoo Finance • 11 months ago

AnaptysBio Inc CEO Daniel Faga Sells 6,866 Shares

AnaptysBio Inc (NASDAQ:ANAB), a biotechnology company engaged in developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, has reported an insider sale according to a recent SEC filing. The insid... Full story

Yahoo Finance • last year

Anaptys Expands Immune Cell Modulator Pipeline with Exclusive License to BDCA2 Modulator Antibody Portfolio from Centessa Pharmaceuticals

Anaptys licenses exclusive global development and commercialization rights to a potential best-in-class BDCA2 modulator portfolio IND filing to support clinical development of ANB101 in autoimmune and inflammatory diseases expected in H2 2... Full story

Yahoo Finance • last year

SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of AnaptysBio, Inc. (NASDAQ: ANAB) and Encourages Investors to Contact the Firm

PHILADELPHIA, Nov. 11, 2023 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating AnaptysBio, Inc. (NASDAQ: ANAB) (“AnaptysBio”) on behalf of the company’s investors. Since November 2022, shares of AnaptysBio’s common... Full story

Yahoo Finance • last year

Anaptys Named a BioSpace 2024 Best Places to Work Winner

SAN DIEGO, Nov. 07, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that, for the second year in a row, it has bee... Full story

Yahoo Finance • last year

INVESTOR ALERT: Abbott Cooper PLLC Announces Investigation into AnaptysBio, Inc.; Urges AnaptysBio’s Stockholders to Contact Abbott Cooper Regarding Their Legal Rights

STAMFORD, Conn., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Abbott Cooper PLLC is investigating AnaptysBio, Inc. (Nasdaq: ANAB) (“AnaptysBio” or the “Company”) on behalf of the Company’s investors. The investigation seeks to determine whether An... Full story

Yahoo Finance • last year

AnaptysBio, Inc. (NASDAQ:ANAB) Is Expected To Breakeven In The Near Future

With the business potentially at an important milestone, we thought we'd take a closer look at AnaptysBio, Inc.'s (NASDAQ:ANAB) future prospects. AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology th... Full story

Yahoo Finance • last year

Anaptys Announces Third Quarter 2023 Financial Results and Provides Business Update

Initiated a global Phase 2b trial to treat rheumatoid arthritis (RA) with rosnilimab, our PD-1 agonist Initiating in Q4 2023 a global Phase 2 trial to treat ulcerative colitis (UC) with rosnilimab Announced positive top-line Phase 3 clin... Full story

Yahoo Finance • last year

Anaptys Announces Participation in November Investor Conferences

SAN DIEGO, Nov. 01, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executiv... Full story

Yahoo Finance • last year

Anaptys to Present Phase 1 Data on ANB032, its BTLA Agonist Antibody, at the 32nd EADV Congress

SAN DIEGO, Oct. 11, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced two upcoming presentations at the 32nd Europea... Full story

Yahoo Finance • last year

Anaptys to Provide Overview of Rosnilimab, a PD-1 Agonist, at Virtual R&D Event on Wednesday, Oct. 25

Webcast at 4:15pm ET/1:15pm PT on Wednesday, Oct. 25 SAN DIEGO, Oct. 09, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today an... Full story

Yahoo Finance • last year

Anaptys Announces Positive Top-Line Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)

53.3% of patients who received a single dose of 750mg IV imsidolimab achieved GPPPGA 0/1 (clear or almost clear) at Week 4 (primary endpoint), compared to 13.3% of patients on placebo (p=0.0131) Demonstrated favorable safety and tolerabili... Full story

Yahoo Finance • last year

AnaptysBio Announces Appointment of John Orwin as Chairman of the Board of Directors

After more than 15 years serving on AnaptysBio’s Board of Directors, Jamie Topper, M.D., Ph.D., is stepping down and will serve as an advisor to the Board through Q1 2024 SAN DIEGO, Sept. 18, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (N... Full story

Yahoo Finance • last year

AnaptysBio to Present at the Stifel 2023 Immunology and Inflammation Virtual Summit

SAN DIEGO, Sept. 12, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executi... Full story

Yahoo Finance • 2 years ago

AnaptysBio Announces British Journal of Dermatology Publication of Imsidolimab (IL-36R) Previously Reported Phase 2 GALLOP Data in Generalized Pustular Psoriasis (GPP)

Rapid and sustained efficacy demonstrated in GPP patients after only a single dose, achieving primary endpoint at Week 4Flare control sustained on monthly subcutaneous doses through Week 16Imsidolimab was generally safe and well tolerated... Full story

Yahoo Finance • 2 years ago

AnaptysBio Announces Appointment of Rita Jain, M.D., to Board of Directors

SAN DIEGO, April 06, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced the appointment of Rita Jain, M.D., to the co... Full story

Yahoo Finance • 2 years ago

AnaptysBio- and GSK-partnered immuno-oncology agent Jemperli (dostarlimab-gxly) plus chemotherapy demonstrates statistically significant and clinically meaningful improvement in progression-free survival for the treatment of primary advanced or recurrent endometrial cancer versus chemotherapy alone in Phase 3 RUBY trial

Results published in TheNew England Journal of Medicine and presented simultaneously at ESMO Virtual Plenary and SGO Annual Meeting72% and 36% reduction in the risk of disease progression or death observed in the dMMR/MSI-H population and... Full story

Yahoo Finance • 2 years ago

AnaptysBio Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Initiating a global Phase 2b trial for rosnilimab (PD-1 agonist) to treat rheumatoid arthritis anticipated Q3 2023Initiating a global Phase 2b trial for ANB032 (BTLA agonist) to treat atopic dermatitis anticipated Q2 2023Initiating second... Full story

Yahoo Finance • 2 years ago

AnaptysBio to Participate at the Cowen and Company 43rd Annual Health Care Conference

SAN DIEGO, Feb. 27, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics today announced that Dan Faga, interim president and chief exec... Full story

Yahoo Finance • 2 years ago

AnaptysBio Announces Stock Repurchase Plan

SAN DIEGO, Jan. 13, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that its Board of Directors has authorized a S... Full story